Prevent bleeding in kids with Hemophilia A who play sports
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study compares two ways to prevent bleeding in people with Hemophilia A while they play sports. It looks at whether factor VIII or emicizumab prophylaxis helps reduce bleeding during higher-risk sports activities.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your parent/legal guardian) can give written consent, and you can agree if you’re a minor
- You’re age 6 to under 20 and have moderate to severe Hemophilia A (very low factor VIII activity) without inhibitors
- You are already using either emicizumab or standard factor VIII preventive treatment
- You are doing—or plan to start—sports that are rated moderate to high risk for bleeding
- You must be willing to keep detailed logs of sports activity, bleeding events, and treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how two different hemophilia A treatments affect bone health over time. It tests if one medicine is better at keeping bones strong than the other.
This trial compares two low-dose medicines to prevent bleeding episodes in people with severe hemophilia A: a newer medicine (emicizumab) versus the standard factor VIII treatment. It may help find a more convenient or effective way to reduce bleeding.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This study tests a medicine called emicizumab, given as a shot under the skin, to see how well it works in children with hemophilia A. It may help prevent bleeding episodes and improve quality of life.
This study tests a new preventive treatment (NXT007) to help stop bleeding episodes in infants and children with hemophilia A. It aims to see if this treatment reduces the number of bleeds and improves quality of life.
This trial tests a study medicine (marstacimab) for children with severe hemophilia A or B, to see if it can help prevent or reduce bleeding episodes. It may be an option for children who do not have certain other health conditions.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.